Skip to main content
. Author manuscript; available in PMC: 2013 Sep 11.
Published in final edited form as: Vaccine. 2012 Apr 3;30(26):3937–3943. doi: 10.1016/j.vaccine.2012.03.071

Table 1.

Enrolled participant characteristics by study site and risk factors*

Vanderbilt
(N=229)
Marshfield
(N=186)
Combined
(N=415)
Age Median (IQR) 57.0
(55.0, 63.0)
73.0
(69.0,77.8)
67.0
(57.0, 74.0)
Age category 50-59 59% 0% 33%
60-69 26% 26% 26%
70+ 15% 74% 41%
Sex Female 67% 52% 60%
Male 33% 48% 40%
Race White 94% 100% 97%
Black 5% 0% 3%
Comorbid conditions Heart disease 7% 9% 7%
Lung disease 10% 8% 9%
Immunosuppressed** 2% 8% 4%
VES-13*** Mean ±SD 1.1±1.3 2.2±2.1 1.6±1.8
BMI Mean ±SD 28.8± 5.7 29.4± 5.4 29.0± 5.6
≥ 30 kg/m2 38% 42% 40%
*

includes subjects who completed 3rd study visit, at which time data related to BMI and vulnerability were assessed

**

Immunosuppressed includes history of transplant, immune dysfunction (including HIV), use of systemic steroid medications, receipt of chemotherapy, or use of other immune modulating medications.

***

Higher VES scores is associated with higher vulnerability.